<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02333084</url>
  </required_header>
  <id_info>
    <org_study_id>PRN 20141</org_study_id>
    <nct_id>NCT02333084</nct_id>
  </id_info>
  <brief_title>The Influence Of a Natural Anti-Inflammatory Product On Levels Of Inflammatory Markers In Cases With Osteoarthritis Of Knee</brief_title>
  <official_title>The Influence Of a Natural Anti-Inflammatory Product On Levels Of Inflammatory Markers In Cases With Osteoarthritis Of Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Physician Recommended Nutriceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rothman Institute Orthopedics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Physician Recommended Nutriceuticals</source>
  <brief_summary>
    <textblock>
      This is a randomized, placebo controlled study. The first subject is expected to be enrolled
      in July 2014, and the last subject is expected to complete the study by July 2015. Each
      subject will be provided with the PRN Joint Comfort Formula, placebo or PRN Flex Omega
      Benefits® combination depending on randomization (1:1:1 at each site) during the course of
      the study. Instructions and frequency of use will be determined by the labelling.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Human Inflammation Multi analyte profile (MAP) v1.0 in Synovial fluid and blood</measure>
    <time_frame>12 weeks</time_frame>
    <description>46 different markers of inaflammation will be studies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores on Visual analog scale</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Joint Health Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>natural dietary supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vegetable oil placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination with Omega-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>combination with omega-3 fish oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PRN Joint Health Formula</intervention_name>
    <arm_group_label>Joint Health Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PRN Flex Omega Benefits® combination</intervention_name>
    <arm_group_label>Combination with Omega-3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 and ≤ 90 at the time of informed consent.

          -  Subjects with symptomatic moderate arthritis of the knee defined as per

          -  Kellgren-Lawrence grade II or III (Appendix B). Subjects with bilateral arthritis of
             the knee will also be recruited, but only one knee will be enrolled into the study.

          -  Ability to walk 50 feet unassisted.

          -  Lequesne's Functional Index score greater than 7 points

        Exclusion Criteria:

          -  Subjects with systemic inflammatory conditions such as inflammatory bowel disease,
             psoriasis, eczema, and others

          -  Subjects with seropositive or sero-negative inflammatory arthritis of the knee such as
             rheumatoid arthritis or ankylosing spondylitis.

          -  Subjects taking hormone replacement therapy

          -  Intra-articular corticosteroid injections 3 weeks prior to enrollment.

          -  Hypersensitivity to fish oil.

          -  Hypersensitivity to non-steroidal anti-inflammatory drugs, abnormal liver of kidney
             function tests, history of peptic ulceration and upper gastrointestinal hemorrhage,
             congestive heart failure, Hypertension (BP&gt;140/90), cancer and hyperkalemia.

          -  Major abnormal findings on complete blood count, history of coagulopathies,
             hematological or neurological disorders.

          -  High alcohol intake (&gt;2 standard drinks per day). Pregnant, breastfeeding or planning
             to become pregnant during the study

          -  Subjects awaiting surgery on the affected knee within three months.

          -  Consumption of any other vitamins/supplements will be allowed, provided the dose is
             not increased, and same brand is continued with. Also, the regimen should not contain
             the same active compounds tested in the PRN Joint health formula product.

          -  Vitamins/supplements cannot be introduced during a subject's participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javad Parvizi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rothman Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rothman Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

